IntoCell, Inc.

₩13,160As of Sun 8 Nov 2026, 12:00 UTC
KOSDAQ:287840Healthcare
Country South Korea
PE (Fwd) •••
TSR 10Y CAGR —
Div yield —
ROE (42.15%)
Biological Products, Except Diagnostic Substances
Beta (5Y) —
PE TTM —
TSR TTM (79.24%)
Mkt cap ₩197.7B
ROIC (17.09%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
₩14,536
10.45%
(39.05%)
Hold 4|6|2|7|7
4Q25
1Q26
2Q26
3Q26
Earnings per share₩
180.19
197.06
215.94
217.20
5.06%
20.25%
33.74%
30.90%
Revenue₩B
10.84
11.46
11.45
11.26
(1.39%)
4.74%
6.31%
1.17%
Peers (US$145.8M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
1.354
(0.147)
(0.135)
EBIT/Intx
3.055
0.333
0.261
Own earn%
116.07
(86.67)
(70.79)
Sh yield%
41.55
37.09
36.36
Owners
Insiders/Inst%
4.71
32.29
Short interest%
4.78
SBC / revenue%
2.88
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
17–25
$1 testx
—
Incr. ROIC%
17